NATCO Pharma Q1 FY27 profit ₹206.5 crore vs ₹480.3 crore; interim dividend ₹1.5
Natco Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Consolidated total revenue ₹794.4 crore for quarter ended 30 June 2026, against ₹1,390.6 crore a year earlier, mainly lower Lenalidomide revenue
- Consolidated net profit ₹206.5 crore against ₹480.3 crore for the year-earlier quarter.
- Board declared interim dividend of ₹1.5 per equity share and will evaluate raising up to ₹2000 crore, subject to shareholder and regulatory approvals.
Why it's rated major development: the year-on-year change is 57% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Natco Pharma
- Fundraise / allotmentNotableNatco Pharma allots 1,70,58,082 equity shares in Rights Issue at ₹750 each
- Board / shareholder meeting outcomeMajor developmentNatco Pharma Limited announces results of 43rd AGM held on 30 September 2026
- Fundraise / allotmentNotableNATCO Pharma Limited files Letter of Offer for Rights Issue closing Oct 22, 2026
- Fundraise / allotmentNotableNatco Pharma board approves rights issue of up to ₹12,79,35,61,500
- Fundraise / allotmentNotableNatco Pharma approves rights issue of up to ₹12,79,35,61,500 via 1,70,58,082 shares
Other dividend / buyback / bonus filings this fortnight
- Premco Global Ltd approves Q2 FY 2026-27 results, declares interim dividend, appoints auditor
- Precision Wires India board approves Sept 2026 quarter results and 35% dividend
- Dynamatic Technologies announces Q2 FY27 financial results and interim dividend
- Great Eastern Shipping approves Q2 and H1 results; declares Rs 14.40 interim dividend
- Safari Industries (India) Limited approves Q2 & H1 FY27 results, interim dividend, capex
- IRB Infrastructure Developers announces Q2 & H1 FY27 results and 2nd interim dividend
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.